前列腺影像报告和数据系统第2版对前列腺癌检测的验证
该前瞻性队列纳入704例接受MRI/超声融合靶向穿刺及10针系统穿刺的男性,评估PI-RADS v2的癌症检出率。结果显示PI-RADS v2 3、4、5类病变的总前列腺癌检出率分别为39%、72%、91%,临床显著前列腺癌检出率分别为23%、49%、77%;仅行靶向穿刺会遗漏16%的临床显著肿瘤。PI-RADS v2评分与前列腺癌、临床显著前列腺癌及ISUP分级均显著相关(p<0.001)。
要点
- PI-RADS v2 3、4、5类的临床显著前列腺癌检出率分别为23%、49%、77%。
- 仅靶向穿刺会遗漏16%的临床显著前列腺癌。
- 靶向穿刺联合系统穿刺可提供最高的临床显著前列腺癌检出。
核心结论
- PI-RADS v2评分与临床显著前列腺癌的存在显著相关(p<0.001)。
- PI-RADS v2 4类病变的癌症检出率 considerably higher than previously reported(原文表述)。
- 靶向穿刺联合系统穿刺仍提供最高的临床显著前列腺癌检出。
研究设计与样本
- 前瞻性队列研究,纳入704例连续男性,均有初次或既往阴性穿刺史。
- 2015年9月至2017年5月期间接受MRI/超声融合靶向穿刺和10针系统前列腺穿刺。
- 所有病变按PI-RADS v2评分,PI-RADS v2≥3类的病变进行穿刺。
- 临床显著前列腺癌定义为ISUP评分≥2(即Gleason 3+4或更高)。
主要发现
- PI-RADS v2 3、4、5类病变的总前列腺癌检出率分别为39%、72%、91%。
- PI-RADS v2 3、4、5类病变的临床显著前列腺癌检出率分别为23%、49%、77%。
- 若仅行靶向穿刺,将遗漏59例(16%)临床显著肿瘤。
- PI-RADS v2评分与前列腺癌、临床显著前列腺癌及ISUP分级均显著相关(p<0.001)。
关键数值与推荐
- PI-RADS v2 3类:总前列腺癌检出率39%,临床显著前列腺癌检出率23%。
- PI-RADS v2 4类:总前列腺癌检出率72%,临床显著前列腺癌检出率49%。
- PI-RADS v2 5类:总前列腺癌检出率91%,临床显著前列腺癌检出率77%。
- 临床显著前列腺癌定义:ISUP评分≥2(Gleason 3+4或更高)。
临床怎么用
- 对PI-RADS v2≥3类病变应进行靶向穿刺。
- 靶向穿刺应联合系统穿刺以避免遗漏临床显著前列腺癌。
- PI-RADS v2 4类病变的癌症检出率较高,需积极活检评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The second version of the PI-RADS™ (Prostate Imaging Reporting and Data System) was introduced in 2015 to standardize the interpretation and reporting of prostate multiparametric magnetic resonance imaging. Recently low cancer detection rates were reported for PI-RADS version 2 category 4 lesions. Therefore the aim of the study was to evaluate the cancer detection rate of PI-RADS version 2 in a large prospective cohort. MATERIALS AND METHODS: The study included 704 consecutive men with primary or prior negative biopsies who underwent magnetic resonance imaging/ultrasound fusion guided targeted biopsy and 10-core systematic prostate biopsy between September 2015 and May 2017. All lesions were rated according to PI-RADS version 2 and lesions with PI-RADS version 2 category 3 or greater were biopsied. An ISUP (International Society of Urological Pathology) score of 2 or greater (ie Gleason 3 + 4 or greater) was defined as clinically significant prostate cancer. RESULTS: The overall cancer detection rate of PI-RADS version 2 categories 3, 4 and 5 was 39%, 72% and 91% for all prostate cancer, and 23%, 49% and 77% for all clinically significant prostate cancer, respectively. If only targeted biopsy had been performed, 59 clinically significant tumors (16%) would have been missed. The PI-RADS version 2 score was significantly associated with the presence of prostate cancer (p <0.001), the presence of clinically significant prostate cancer (p <0.001) and the ISUP grade (p <0.001). CONCLUSIONS: PI-RADS version 2 is significantly associated with the presence of clinically significant prostate cancer. The cancer detection rate of PI-RADS version 2 category 4 lesions was considerably higher than previously reported. When performing targeted biopsy, the combination with systematic biopsy still provides the highest detection of clinically significant prostate cancer.
引用
- Hofbauer SL, Maxeiner A, Kittner B, et al. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer. J Urol. 2018. PMID: 29733838. doi:10.1016/j.juro.2018.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。